Oncology Data Advisor

Read the full article here: https://oncdata.com/information-overload-and-the-portal-patient

The way that patients receive medical information has changed dramatically. Through electronic health record portals, laboratory values, imaging reports, and pathology results often become available the moment they are finalized—sometimes before a physician has had the opportunity to review or discuss them. While this unprecedented access promotes transparency and patient engagement, it also creates new challenges for communication, trust, and anxiety management. In the latest episode of Oncology Unfiltered, Melissa Cutrona, Co-Founder and General Manager of i3 Health and Oncology Data Advisor, sits down with Matthew Hadfield, DO, Oncology Data Advisor Editor in Chief, to explore how instant access to test results is reshaping oncology care.

Read the full article here! https://oncdata.com/personalizing-cancer-prevention-ai-enhanced-imaging

As healthcare increasingly shifts from reactive treatment to proactive prevention, artificial intelligence (AI) is emerging as a powerful tool for identifying disease earlier and personalizing patient care. In this episode of Exploring AI in Oncology, Dr. Waqas Haque, Hematology/Oncology Fellow at the University of Chicago, spoke with Dr. Sean Raj, Chief Innovation Officer and Chief Medical Officer at SimonMed, about how AI is transforming cancer detection, risk assessment, and patient education. Their conversation highlights how advanced imaging technologies are helping patients gain earlier insights into their health while empowering clinicians with new tools for preventive care.

Frontline treatment selection for newly diagnosed multiple myeloma (NDMM) is more complex than ever. With quadruplet regimens and anti-CD38 antibodies redefining the landscape, how do you choose the right therapy for each unique patient?

In this exclusive preview, Ashley Chen, PharmD, BCOP (Fred Hutchinson Cancer Center), shares actionable insights on:

🔹The Nuances of Modern Selection: Balancing comorbidities and logistical hurdles.
🔹Managing Induction Burden: Proactive strategies for steroid side effects and neuropathy.
🔹Pragmatic Dosing: Finding the most sustainable, real-world dose for frail or older patients.

📅 Save Your Spot for the Live Event!
Get case-based guidance from Dr. Rahul Banerjee, Dr. Ashley Chen, and Dr. Beth Faiman.
Session 1: July 8 at 6:00 pm ET: bit.ly/3SitVaC
Session 2: July 28 at 7:00 pm ET: bit.ly/4oIAcZo

View the full article at: https://oncdata.com/oncology-unfiltered-tumor-board-vs-tuesday-afternoon

Tumor boards play a pivotal role in oncology care. For clinicians, they represent the ideal environment: multiple specialists, shared context, and time to debate the gray areas that guidelines can’t fully capture. However, during a busy afternoon in the clinic, the plans developed in tumor boards often prove less straightforward to implement. In this episode of Oncology Unfiltered, Melissa Cutrona, MS, and Matthew Hadfield, DO, OncData Editor in Chief, unpack why tumor boards are so valuable, where they fall short, and how to bridge the gap between a coordinated plan and the reality of care delivery on a busy clinic day.

Check out the full article at: https://oncdata.com/oncology-unfiltered-the-real-world-vs-the-trial-patient

Every oncologist knows the moment well: you're reviewing treatment options with a patient, guidelines in hand, when you realize the person sitting across from you wouldn't have qualified for the pivotal trial that established your recommended therapy. In this episode of Oncology Unfiltered, Melissa Cutrona, Co-Founder and General Manager of i3 Health and Oncology Data Advisor, speaks with Dr. Matthew Hadfield, Oncology Data Advisor Editor in Chief, about one of oncology's most persistent challenges—the widening gap between carefully curated trial populations and the complex, real-world patients who enter clinics daily.